A phase 2 double-blind dose escalation study of KRN5500 for neuropathic pain in patients with cancer.

Trial Profile

A phase 2 double-blind dose escalation study of KRN5500 for neuropathic pain in patients with cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2012

At a glance

  • Drugs KRN 5500 (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 May 2012 Results published in a DARA BioSciences media release
    • 16 Aug 2011 Results accepted for publication by a peer-reviewed medical journal, according to a DARA BioSciences media release.
    • 01 Feb 2011 Results from analyses of this study exploring placebo response will be presented at the International Conference on Accelerating the Development of Enhanced Pain Treatments (ADEPT) to be held in March 2011, as reported in a DARA Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top